A New Hormonal Therapy for Estrogen Receptor–Negative Breast Cancer

Hardin, Chelsea; Pommier, Rodney; Calhoun, Kristine; Muller, Patrick; Jackson, Terisa; Pommier, SuEllen
May 2007
World Journal of Surgery;May2007, Vol. 31 Issue 5, p1041
Academic Journal
We postulate that the androgen dehydroepiandrosterone sulfate (DHEAS) may represent an innovative hormonal treatment for estrogen (ER), progesterone (PR) receptor–negative, but androgen receptor (AR)–positive breast cancers by inhibiting breast cancer cell growth through AR stimulation. Three ER,PR–negative breast cancer cell lines (HCC 1137, 1954, and 38), were treated with DHEAS. DHEAS-induced growth was measured by a methylthiotetrazole (MTT) proliferation assay and apoptosis by TUNEL fluorescence. Androgen receptor gene expression levels were determined using quantitative real-time polymerase chain reaction (q-RT-PCR). HCC cell lines 1954 and 1937 were positive for AR expression; HCC 38 was weakly positive. MTT analysis showed DHEAS-induced decreases in cell proliferation of 47% in HCC 1937, 27% in HCC 1954, and 0.4% in HCC 38. Ten days of culturing HCC 1954 cells after the removal of DHEAS resulted in a 3.5-fold increase in growth. Continuous treatment for the same duration induced a 2.8-fold decrease in growth. Parallel experiments showed no significant changes in HCC 38 cultures. TUNEL assays showed DHEAS-induced apoptosis fold increases of 2.8 in HCC 1937, 1.9 in HCC 1954, and no significant difference in HCC 38 cultures. Q-RT-PCR of HCC 1954 cells showed a 6-fold DHEAS-induced decrease in AR gene expression at 4 h. Co-treatment with Casodex nullified this effect. DHEAS inhibited growth of ER,PR–negative, AR–positive breast cancer cells. DHEAS was cytotoxic to these breast cancer cells via the apoptosis pathway. DHEAS may be an effective treatment for a population previously excluded from hormone therapy.


Related Articles

  • Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Singer, Christian F.; Bennink, Herjan J.T.Coelingh; Natter, Camilla; Steurer, Stefan; Rudas, Margaretha; Moinfar, Farid; Appels, Nicole; Visser, Monique; Kubista, Ernst // Carcinogenesis;Nov2014, Vol. 35 Issue 11, p2447 

    The results of our placebo-controlled Phase II trial demonstrate antitumoral effects of the fetal estrogen E4 on endocrine-responsive breast cancer. They suggest that E4 can be used as hormone replacement therapy in healthy women and in breast cancer patients.Estetrol (E4) is a fetal estrogen...

  • Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. Kok, Marleen; Holm-Wigerup, Caroline; Hauptmann, Michael; Michalides, Rob; Stål, Olle; Linn, Sabine; Landberg, Göran // JNCI: Journal of the National Cancer Institute;12/16/2009, Vol. 101 Issue 24, p1725 

    Although estrogen receptor-α (ERα) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERα-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERα at...

  • High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Endo, Yumi; Toyama, Tatsuya; Takahashi, Satoru; Sugiura, Hiroshi; Yoshimoto, Nobuyasu; Iwasa, Mai; Kobayashi, Shunzo; Fujii, Yoshitaka; Yamashita, Hiroko // International Journal of Clinical Oncology;Oct2011, Vol. 16 Issue 5, p512 

    Background: Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, many breast cancer patients with tumors expressing ER are unresponsive to aromatase inhibitors, and all patients with advanced...

  • A Functionally Significant Cross-talk between Androgen Receptor and ErbB2 Pathways in Estrogen Receptor Negative Breast Cancer. Naderi, Ali; Hughes-Davies, Luke // Neoplasia;Jun2008, Vol. 10 Issue 6, p542 

    Recent studies have identified novel subgroups in ER-negative breast cancer based on the expression pattern of androgen receptor (AR). One subtype (molecular apocrine) has an over-expression of steroid-response genes and ErbB2. Using breast cancer cell lines with molecular apocrine features, we...

  • Src: a potential target for the treatment of triple-negative breast cancer. Tryfonopoulos, D.; Walsh, S.; Collins, D. M.; Flanagan, L.; Quinn, C.; Corkery, B.; McDermott, E. W.; Evoy, D.; Pierce, A.; O’Donovan, N.; Crown, J.; Duffy, M. J. // Annals of Oncology;Oct2011, Vol. 22 Issue 10, p2234 

    Background: Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2). Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients. The aim of...

  • Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes. Nagai, M. A.; Brentani, M. M. // Mini Reviews in Medicinal Chemistry;May2008, Vol. 8 Issue 5, p448 

    The estrogens play important role in the homeostatic maintenance of several target tissues including those in the mammary gland, uterus, bone, cardiovascular system, and brain. Most of estrogen's action is thought to be mediated through its nuclear estrogen receptors, ERβ and ERβ, which...

  • Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Oliver Treeck; Ingolf Juhasz-Boess; Claus Lattrich; Felicitas Horn; Regina Goerse; Olaf Ortmann // Breast Cancer Research & Treatment;Aug2008, Vol. 110 Issue 3, p507 

    Abstract  Estrogen receptor β gene codes for a variety of transcript isoforms resulting from alternative splicing, which are expressed both in mammary gland and in breast cancer cells. We studied the function of two exon-deleted ERβ isoforms recently identified by our group in...

  • Oestrogen receptors and breast cancer. Elledge, Richard M.; Osborne, C. Kent // BMJ: British Medical Journal (International Edition);06/28/97, Vol. 314 Issue 7098, p1843 

    Editorial. Discusses how estrogen receptors affect a breast cancer patient's response to endocrine treatments. Predictor of benefit of tamoxifen in preventing or delaying recurrence; Assay methods available in determining estrogen receptor status.

  • Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Dressman, M. A.; Walz, T. M.; Lavedan, C.; Barnes, L.; Buchholtz, S.; Kwon, I.; Ellis, M. J.; Polymeropoulos, M. H. // Pharmacogenomics Journal;2001, Vol. 1 Issue 2, p135 

    Presents a study that examined the role of estrogen receptors in the pathogenesis and clinical behavior of breast cancer. Analysis of the gene expression of the breast cancer biopsies; Evaluation of the immunochemistry of the samples; Examination of the co-clustering of the genes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics